Utility and limitations of biochemical markers of vitamin B12 deficiency
Article first published online: 18 JAN 2013
© 2012 The Authors. European Journal of Clinical Investigation © 2012 Stichting European Society for Clinical Investigation Journal Foundation
European Journal of Clinical Investigation
Volume 43, Issue 3, pages 231–237, March 2013
How to Cite
Eur J Clin Invest 2013; 43 (3): 231–237
- Issue published online: 14 FEB 2013
- Article first published online: 18 JAN 2013
- Accepted manuscript online: 27 NOV 2012 05:25PM EST
- Manuscript Accepted: 21 NOV 2012
- Manuscript Received: 16 FEB 2012
Figure S1. Diagnostic algorithm starting with holoTC as a first line markers then MMA as a second line marker.
Figure S2. The correlation between serum MMA and holoTC according to serum creatinine.
Figure S3. Number of cases with holoTC in the gray range according to concentrations of MMA and serum creatinine.
Figure S4. The correlation between the reduction in MMA and baseline holoTC in renal patients (the majority of them had severely elevated MMA) treated with vitamin B12 over 1 month.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.